Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity

[1]  Georg H. H. Borner.  Organellar Maps Through Proteomic Profiling - A Conceptual Guide. , 2020, Molecular & cellular proteomics : MCP.

[2]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[3]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[4]  Jason D. Buenrostro,et al.  The cis-Regulatory Atlas of the Mouse Immune System , 2019, Cell.

[5]  S. Amigorena,et al.  Regulation of Antigen Export to the Cytosol During Cross-Presentation , 2019, Front. Immunol..

[6]  E. Lundberg,et al.  Spatial proteomics: a powerful discovery tool for cell biology , 2019, Nature Reviews Molecular Cell Biology.

[7]  Georg H. H. Borner,et al.  Dynamic Organellar Maps for Spatial Proteomics , 2018, Current protocols in cell biology.

[8]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[9]  Y. Assaraf,et al.  Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity , 2018, Cell Death & Disease.

[10]  M. Diamond,et al.  WDFY4 is required for cross-presentation in response to viral and tumor antigens , 2018, Science.

[11]  C. Reis e Sousa,et al.  The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity , 2018, Trends in cancer.

[12]  S. Quezada,et al.  Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming. , 2018, Cancer research.

[13]  A. Alice,et al.  Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity , 2018, Scientific Reports.

[14]  J. Cox,et al.  A Mass Spectrometry-Based Approach for Mapping Protein Subcellular Localization Reveals the Spatial Proteome of Mouse Primary Neurons , 2017, Cell reports.

[15]  M. Albert,et al.  Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity , 2017, The Journal of experimental medicine.

[16]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[17]  P. Cresswell,et al.  Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export , 2017, Proceedings of the National Academy of Sciences.

[18]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[19]  Fiorella Kotsias,et al.  Dendritic cell maturation and cross‐presentation: timing matters! , 2016, Immunological reviews.

[20]  J. Cox,et al.  Global, quantitative and dynamic mapping of protein subcellular localization , 2016, eLife.

[21]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[22]  María Martínez-López,et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.

[23]  A. Koster,et al.  The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells. , 2015, Immunity.

[24]  Marco Y. Hein,et al.  A “Proteomic Ruler” for Protein Copy Number and Concentration Estimation without Spike-in Standards* , 2014, Molecular & Cellular Proteomics.

[25]  P. Kloetzel,et al.  Cross-Presentation of Synthetic Long Peptides by Human Dendritic Cells: A Process Dependent on ERAD Component p97/VCP but Not sec61 and/or Derlin-1 , 2014, PloS one.

[26]  M. Mann,et al.  Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells , 2014, Nature Methods.

[27]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[28]  O. Kirak,et al.  A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. , 2013, Blood.

[29]  I. Mellman,et al.  Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. , 2012, Blood.

[30]  M. Mann,et al.  Novel Murine Dendritic Cell Lines: A Powerful Auxiliary Tool for Dendritic Cell Research , 2012, Front. Immun..

[31]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[32]  F. Randow,et al.  Galectin-8 targets damaged vesicles for autophagy to defend cells against bacterial invasion , 2011, Nature.

[33]  J. Enninga,et al.  Sec22b Regulates Phagosomal Maturation and Antigen Crosspresentation by Dendritic Cells , 2011, Cell.

[34]  Yvonne Will,et al.  A high content screening assay for identifying lysosomotropic compounds. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[35]  K. Kamiguchi,et al.  Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells. , 2011, International immunology.

[36]  E. Janssen,et al.  Prolonged Antigen Storage Endows Merocytic Dendritic Cells with Enhanced Capacity To Prime Anti-Tumor Responses in Tumor-Bearing Mice , 2010, The Journal of Immunology.

[37]  J. Kornhuber,et al.  Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications , 2010, Cellular Physiology and Biochemistry.

[38]  E. Unanue,et al.  Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation , 2009, Proceedings of the National Academy of Sciences.

[39]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[40]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[41]  M. Colonna,et al.  DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.

[42]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[43]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[44]  M. Wright,et al.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. , 2008, Blood.

[45]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[46]  R. Tampé,et al.  Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation , 2008, Nature Immunology.

[47]  Peter Cresswell,et al.  Hsp90-mediated cytosolic refolding of exogenous proteins internalized by dendritic cells , 2007, The EMBO journal.

[48]  G. Raposo,et al.  Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes , 2007, Nature Cell Biology.

[49]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[50]  V. Cerundolo,et al.  Role of Immunoproteasomes in Cross-Presentation1 , 2006, The Journal of Immunology.

[51]  C. Hotta,et al.  The delivery of an antigen from the endocytic compartment into the cytosol for cross‐presentation is restricted to early immature dendritic cells , 2006, Immunology.

[52]  K. Rock,et al.  Cross‐presentation: underlying mechanisms and role in immune surveillance , 2005, Immunological reviews.

[53]  D. Accapezzato,et al.  Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo , 2005, The Journal of experimental medicine.

[54]  S. Koyasu,et al.  Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. , 2005, International immunology.

[55]  K. Rock,et al.  Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. , 2004, Immunity.

[56]  R. Tampé,et al.  Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Davoust,et al.  ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells , 2003, Nature.

[58]  S. Akira,et al.  A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells1 , 2003, The Journal of Immunology.

[59]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[60]  G. Hartmann,et al.  Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1 , 2000, The Journal of Immunology.

[61]  Sebastian Amigorena,et al.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells , 1999, Nature Cell Biology.

[62]  G. Zlokarnik,et al.  Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. , 1998, Science.

[63]  K. Rock,et al.  Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity , 1995, Nature Medicine.

[64]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[65]  N. Shastri,et al.  LacZ inducible, antigen/MHC-specific T cell hybrids. , 1994, International immunology.